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Abstract
Polypharmacy and physiological changes inherent to the aging process can cause 
significant modifications in the pharmacokinetic and dynamic regimens of drugs, 
making the elderly more susceptible to adverse drug effects. Adverse drug reactions 
(ADR) in older adults have a significant impact on hospital admissions, increasing 
hospital stay and healthcare costs. Most common ADR in this population are dose-
related and predictable. However, they can be difficult to diagnose as they often 
have nonspecific symptoms. This could be minimized by decreasing the use and 
prescription of potentially inappropriate medication and being aware of possible 
drug interactions. Besides, being older patients underrepresented in clinical trials 
and due to their physiological modifications, serious or atypical ADR are more 
common in this age range. To minimize harm in older adults, effective pharmaco-
vigilance must be encouraged.
Keywords: Elderly, Medication, Adverse Drug Reactions, Drug Safety, 
Pharmacovigilance
1. Introduction
The World Health Organization [WHO] estimates that more than half of medi-
cines are either inappropriately prescribed, dispensed, or sold, as the vast majority 
of patients fail to take their medication properly [1]. Adding the fact that no drug, 
taken correctly, is completely risk-free, it becomes of the outmost importance to 
permanently monitor its safety, to ensure that, throughout its life cycle, the benefits 
of each drug outweigh the risks of its use [2]. Pharmacovigilance intends to promote 
patient care and safety as well as an effective assessment of the risk–benefit profile 
of drugs [3].
With declining fertility rates and greater and better access to health care, the 
population aged, and the number of older adults has increased globally [4].
Aging is a risk factor for the development of chronic diseases, and to an 
increased incidence of pathologies such as cardiovascular diseases, strokes, cancer, 
or dementias. In this sense, the older population is the age group that most needs 
health care and medicines [5, 6]. Polypharmacy, commonly defined as the concomi-
tant use of at least five drugs, is thus prevalent in this age group [7, 8].
Associated with aging, pharmacodynamic and pharmacokinetic changes occur 
at physiological level, which implies modified pharmacological responses [9]. The 
older are much more susceptible to adverse reactions and drug interactions than any 
other age group [7, 8].
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Since people aged 65 and older are underrepresented in clinical trials pharma-
covigilance becomes essential to allow continuous monitoring of safety and the 
assessment of the benefit/risk of drugs in this population [10].
2. Physiological and pharmacological modifications
The impact of aging on the human organism brings together complex changes 
at the molecular, cellular and tissue levels in all systems of the organism, and the 
effects of the most varied existing environmental factors [11, 12].
The physiological changes associated with the aging process weaken the older 
population. These can cause significant changes in the pharmacokinetic and 
dynamic regimens of medications, making them more susceptible to adverse 
effects [13].
2.1 Age-related changes in pharmacokinetics
With aging, pharmacokinetics processes suffer modifications [9]. Bioavailability, 
the extent and rate at which the active substance enters the systemic circulation to 
reach the action site, can be modified [9, 14].
Absorption of most drugs does not appear to decrease significantly with age, 
but different pathologies of the digestive system may affect drug absorption [9]. 
Nevertheless, drugs administered intramuscularly or subcutaneously may have 
their absorption modified, due to the reduction in blood perfusion of the  
tissues [15].
After absorption, the drug enters the bloodstream and is distributed to different 
tissues and organs. With the increase in fat mass and reduction in the volume of 
water, the volume of distribution of fat-soluble medications increases [as does the 
half-life of the same], as in the case for the long-acting benzodiazepines [15, 16]. 
In contrast, water-soluble drugs may have a lower volume of distribution, with an 
increase in plasma concentrations, that can be toxic, as happens with gentamicin, 
digoxin, theophylline, and cimetidine [9, 16]. In addition to body composition, 
the two main proteins involved in the transport of drugs: albumin, which binds to 
acidic drugs [e.g. warfarin, digoxin, lorazepam], and α1-acid glycoprotein, which 
binds mainly to basic drugs [ex: lidocaine, propranolol] may have their plasma 
concentrations altered in older population with comorbidities [15, 17].
Although other organs can metabolize drugs, the liver is the main organ involved 
in the process. Metabolism consists of converting an active substance in simpler 
and more polar substances, called metabolites, from phase I and II reactions. 
These metabolites are inactive or have modified activity. In the liver, maintain-
ing its functions during aging, there are changes that can reduce its functionality 
[18]. The hepatic volume decreases 20–30%, and the hepatic blood flow 20–50%. 
There is a reduction in the first-pass hepatic effect, and thus the bioavailability of 
drugs that are subjected to extensive first-pass metabolism may be increased, while 
others, which need activation in the liver, may be reduced [15]. In addition, the 
hepatic clearance of drugs subjected to limited flow metabolism [e.g., propranolol 
and amitriptyline] can be reduced by more than 40%. Age can significantly affect 
the pharmacokinetics of drugs with a narrow therapeutic index [reduced margin 
between an effective dose and a toxic dose]. Inflammatory conditions can also affect 
the function of the enzymes involved in metabolism. The microbial ecosystem also 
stands out, with many clinically relevant drugs being co-metabolized by microflora. 
With changes in the composition of the intestinal microbiome, the drug’s metabo-
lism can also be altered with harmful consequences [19].
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Excretion is also affected by the aging process. The kidney is the main organ in 
the removal of drugs and their metabolites and the pharmacokinetics are strongly 
influenced by the progressive loss of kidney function with age, thereby decreasing 
the excretion of drugs [20, 21]. Due to these changes, a decline in total clearance 
with age is expected for drugs predominantly excreted by this pathway. With the 
decrease in clearance, serum levels will increase, potentially causing ADR [22]. 
Therefore, the dosage of these drugs must be guided by kidney function and the 
glomerular filtration rate [GFR]. In addition, polypharmacy can increase the risk 
of kidney dysfunction, overloading the kidneys to excrete several drugs and their 
metabolites at the same time [23].
2.2 Age-related changes in pharmacodynamics
In older adults’ sensitivity, meaning the effects of the same concentration of 
a particular drug at the site of action, vary significantly when comparing with 
young or adult persons. This difference can be justified by changes in drug-receptor 
interaction, signal transduction, adaptive homeostatic responses and, among more 
fragile patients, by comorbidities [24, 25]. Although age-related pharmacokinetic 
changes are predictable, the complex interaction between pharmacokinetic changes 
and homeostatic changes makes it a difficult topic to study [15].
The most relevant pharmacodynamic changes are at the central nervous system 
[CNS] and cardiovascular level [15]. Older adults often demonstrate an exaggerated 
response to psychoactive drugs due to an underlying age-related decline in CNS 
function, and are also more prone to adverse effects with cognitive impairment, 
including confusion and drowsiness. At the cardiovascular level, they may experi-
ence a greater decline in blood pressure after administration of calcium channel 
blockers with or without dihydropyridine, which may be the result of related changes 
with age in the reflex of the baroreceptors, as well as a decreased clearance of these 
drugs [25, 26]. In addition, β-adrenergic receptors decrease in numbers and have less 
sensitivity and also show changes in the G-protein involved in signal transduction. 
As a result, β-adrenergic activity in vascular, cardiac and respiratory tissue decreases, 
altering the effect of β-blocking agents and β-agonists in general [26, 27].
Pharmacodynamics not only affects the therapeutic effects of the drug but can 
also change the magnitude of the effect with subsequent adverse effects [20, 25]. 
These changes in pharmacokinetics and pharmacodynamics can thus make the 
older population more prone and susceptible to ADRs, either in normal therapeutic 
doses or by drug interactions mechanisms [27].
3. Adverse drug reactions in older adults
As previous mentioned, physiological aging causes pharmacodynamic and 
pharmacokinetic changes, imposing different pharmacological responses [9]. The 
drug could trigger iatrogenic problems in the geriatric patient, increasing the risk of 
possible ADR [28].
The vast majority of ADRs can be divided in 2 types:
• Dose-dependent, more frequent at higher doses, which can occur in any 
individual when exposed to a sufficient dose of the drug: Type A - Augmented, 
representing almost 80% of all ADR in older patients [29, 30]
• Immune mediated or non-immunological hypersensitivity reactions, not 
dependent on the dose, which can occur in predisposed individual. These 
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reactions are therefore unpredictable and more serious, usually detected only 
after the drug enters the market: Type B - Bizarre, representing 20% of all 
ADRs in older patients [29–32].
Drugs associated with type A reactions are generally of low therapeutic index 
and are commonly used in older patients and therefore most ADRs in this age group 
are type A reactions with predictable pharmacological effect [30, 33]. Known 
homeostatic dysregulation, age-related changes in pharmacokinetics and pharma-
codynamics and drug interactions make ADRs definitely or possibly preventable 
in this population. However, ADRs can be difficult to diagnose in older patients as 
they often have nonspecific symptoms, whether falls, fatigue, cognitive decline, or 
constipation, all of which have different etiologies [7]. Despite the difficulties it is 
estimated an average prevalence of 11% of ADR [33].
Most common ADRs causing hospitalization in older patients are related to 
Gastrointestinal complications [Gastrointestinal bleeding, peptic ulcer, erosive 
gastritis, nausea, vomiting]; Cardiovascular disorders [Hypotension, bradycardia, 
falls, arrhythmias] Metabolic/endocrine complications [Hypoglycemia]; Renal 
and urinary disorders [Renal impairment, acute renal failure]; Electrolyte dis-
orders [Hypokalemia, hyperkalemia, hyponatremia]; Nervous system disorders 
[Depressed level of consciousness, mental status changes] [34]. Studies have 
shown that beta-blockers, antibiotics, oral anticoagulants, digoxin, ACE inhibi-
tors, antineoplastics, calcium entry blockers, opioids, oral antidiabetics and most 
frequently NSAIDs as the main drug classes causing ADR hospitalization in older 
adults [33, 35].
3.1 The healthcare impact of ADR in older patients
ADRs cause a significant burden in healthcare services, representing 6.5% in 
hospital admissions, being responsible for death of 0.15% of the patients admitted. 
Besides, patients admitted with ADRs were significantly older than patients without 
ADRs, as hospitalization due to NSAIDs complications increases exponentially with 
aging, having an important impact in healthcare resources. The median prevalence 
of ADRs leading to hospitalization is 10%. Although some hospitalizations related 
to ADRs are inevitable, it is estimated that only 18.6–28% of ADR cases that caused 
hospitalization in older patients were considered inevitable. Severe ADRs are 
related mostly to hematological disorders and acute renal failure [33, 34].
Polypharmacy is one of the main risk factors for ADR in this population. The 
risk of ADR increases by 13% in patients taking two drugs to 58% when taking five 
and to 82% when taking seven or more drugs [4, 7]. Drug interactions, common in 
polypharmacy, can cause synergistic toxicity and thus be risk factors, such as the 
combination of corticosteroids and NSAIDs. Polypharmacy leads to problems in 
medication adherence and correct administration representing a risk for adverse 
events or ADR [31, 36, 37].
ADRs also have a strong economic impact in the health system. The costs 
involved in treatment are mainly associated with hospitalization, prolonged 
hospital stay and additional clinical investigations- Studies point to an average of 8 
additional hospital stay days and costs of approximately 706 M € per year [38, 39]. 
Regarding avoidable ADRs, costs per hospitalization vary between € 2,851 - 9,015, 
with length of hospital stay between 4.2 and 13 days. In outpatient, the costs result-
ing from avoidable ADRs ranged between € 174 and € 8,515 [38]. Particularly in the 
elderly, an average cost of emergency care of 333 US $ is pointed, with severe ADR 
patients costing $ 691 per patient and $ 7,529 per patient with severe ADR during 
hospitalization [40].
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ADRs can trigger cascades of prescription when new drugs are prescribed for 
problems resulting from another medication, which is usually an unknown ADR, 
increasing therapeutic costs, in addition to increasing the risk of new ADRs. Fever, 
hemorrhage, diarrhea and arrhythmia are those with the greatest economic burden 
in a hospital environment; and NSAIDs, antibiotics, anticoagulants and antineo-
plastics are the main classes involved in ADRs related costs [39].
Most drugs are suitable for the older, as long as they are used in the correct dose 
and for the necessary period. However, since they are more susceptible to adverse 
events, the potential risk of certain drugs may outweigh the potential benefit. 
When safer alternatives are available, these drugs are considered inappropriate 
[PIM] [28, 41].
3.2 Potentially inappropriate medication for older adults
In recent years, in order to reduce inappropriate prescribing, and in turn, to 
reduce the prevalence of PIM in older population, explicit and implicit criteria 
strategies and tools have been developed, being very useful in clinical practice, as 
decision support- Explicit criteria consists in lists of drugs applied with minimal 
information and clinical evaluation, not considering individual differences between 
patients, representing important alert mechanisms on the possibility of the inap-
propriate use of a medication just by itself, as where implicit criteria focus on the 
patient’s therapeutic regimen and clinical evaluation. Associating these criteria with 
information management tools such as Clinical decision support systems [CDSS] 
can allow improvements in patient therapy. These CSSDs, usually computerized, 
can verify interactions between medicine-disease or medicine-medicine, also 
detecting PIM [36].
Among the criteria most applied in research within this theme, Beers criteria 
stands out. In 1991, Beers and his research colleagues met with geriatric and 
pharmaceutical specialists to list the drugs to be avoided by older people. Explicit 
criteria were defined, considering 30 drugs/pharmacological groups considered 
inappropriate. These criteria have since been repeatedly reformulated and updated 
according to new information in the literature. Currently, these criteria are divided 
into 5 lists: Potentially inappropriate to be avoided in the elderly; Potentially inap-
propriate in the elderly due to drug–drug and/or drug-disease interactions; Those 
that should be prescribed with caution in the elderly; Combinations of drugs known 
to cause “drug–drug” interactions; Drugs to be avoided or whose dose adjustment is 
necessary when prescribed in elderly people with impaired renal function [42, 43]. 
However, its application in Europe is limited, where several of the drugs identified 
in these criteria are not commercialized in this continent and some of the drugs 
marketed in Europe are inappropriate and are not on the Beers list [44].
START/ STOPP criteria is also currently used. The STOPP [Screening Tool of 
Older Person’s potentially inappropriate Prescriptions] criteria are 80 parameters 
organized by physiological systems. The START [Screening Tool to Alert doctors 
to Right Treatment], on the other hand, identify potentially beneficial omissions 
[which should be prescribed to the elderly], with 34 criteria divided into six physi-
ological systems [44]. STOPP/START have advantages over Beers because they are 
significantly associated with adverse drug reactions. In addition, they are more 
in line with the European reality, also having greater sensitivity demonstrated for 
the identification of inappropriate prescriptions. Although the STOPP criteria is 
explicit, only 29 of the 81 STOPP criteria can be applied only with information on 
the patient’s medication profile [36].
Recently, in order to develop a European list of potentially inappropriate drugs, 27 
experts from 7 countries in Europe came together, creating the EU [7] -PIM list, with 
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282 drugs from 34 pharmacological classes in which it is found, for each drug, the 
justification for its inadequacy, as well as dose adjustments/special considerations of 
use [when applicable] and possible alternatives to that drug [45].
The EU [7]-PIM list has been used in some studies in Europe that show a range 
between 40.9 [Sweden] and 87% [Portugal] of older adults having PIM prescribed 
by the physician. Proton bomb inhibitors, Bromazepam, Diazepam, Lorazepam and 
Alprazolam are the most common [46].
ADRs related to PIMs were observed in some studies, with digoxin, benzodiaz-
epines, and imipraminic antidepressants, being the most common. In hospitalized 
older patients, NSAIDs were the most common types of PIM-ADRs, inducing 
upper gastrointestinal bleeding. Benzodiazepines inducing falls with fractures and 
depressed mental status, as well as digoxin >0.125 mg/day inducing cardiac arrhyth-
mias and visual disturbances due to digoxin poisoning are also common in hospital 
context [47, 48].
4. Promoting drug safety in older adults
Older adults have a higher chronic diseases burden and consume more pre-
scription drugs than any other age group. Besides drug–drug interactions, the 
prevalence of concurrent use of prescription drugs and herbal medicinal products 
[HMPs] by older adults is significant, and can also lead to serious ADR, as risk of 
bleeding due to the use concomitant use of Ginkgo biloba, garlic or ginseng with 
antithrombotics [49].
4.1 Older participants in clinical trials
Including older patients in the clinical trial process is important, as on average 
older adults carry 60% of the national disease burden but represent only 32% of 
participants in Phase II and III clinical trials [50, 51]. This population is under-
represented, especially the >75-year-old. and current guidelines recommend to 
have a significant number of older participants in the trials [that can be estimated 
with the help of epidemiological studies targeting the disease that the drug intends 
to treat] in order to assess the risk–benefit ratio of the drug in this age group. Phase 
I trials might not need older participants, but phase II and III clinical trials should 
include them, to assess dosage, safety, adverse effects, and effectiveness [52, 53]. 
Decentralized clinical trials could facilitate the appropriate inclusion of these 
patients [50].
Nevertheless, including this age group implies some methodological consid-
erations. As it exists a progressive impairment of the renal or hepatic function or 
drug–drug interactions, an appropriate assessment of pharmacokinetic profiles 
and pharmacodynamic endpoints are needed [54, 55]. Besides, since they have a 
high risk of cognitive function impairment, determining adverse CNS events is of 
the outmost relevant clinical importance during the trial design. Aware of these 
needs, the International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use [ICH] developed guidelines for studies in special 
populations, namely older adults, aiming for a sufficient representation in phase III. 
It is advisable 100 minimum participants and, when the disease is associated with 
aging, older people should form most of the participants [55, 56].
These studies should compare older and younger patients or evaluate drug 
disease interaction studies in older adults. Population pharmacokinetic analyses 
intends to determine the sources and correlation of variability of the drug concen-
tration in the target patient population, comparing the older with the young group. 
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Safety and efficacy should also be of the outmost importance, as outcomes must 
be explored to provide evidence base support to the dose selection during drug 
approval, impacting regulatory procedures. Finding significant differences in safety 
and efficacy outcomes between young and older patients, pharmacokinetic studies 
plays an important role to understand these differences and assess benefit–risk of a 
drug administration [55–57].
4.2 Medication labelling
After drug development, providing quality information to health care profes-
sionals about the safe and effective use of drugs in geriatric patients is fundamen-
tal. And so, it is required by the Food and Drug Administration [FDA] and the 
European Medicines Agency [EMA] that the labeling of these drugs must have 
safety and efficacy information for the older. Particularly for EMA, it is mandatory 
to present on the Summary of Product Characteristics [SmPC] and the Patient 
Information Leaflet information regarding dosage, frequency and seriousness of 
ADR, or the need of monitoring in this population [57, 58].
4.3 Pharmacovigilance in older patients
Pharmacovigilance plays a key role in ADR detection in post authorization 
period, improving the safe and rational drug use and thereby improving patient 
care [59, 52]. In 2012, new legislation came into force within EU, creating the 
Pharmacovigilance Risk Assessment Committee and giving a central role to 
pharmacovigilance. A significant increase in the participation of health profes-
sionals and patients in the system was seen, and the electronic transmission of 
information from Pharmacovigilance became mandatory in November 2005, with 
EudraVigilance being the system for analyzing and managing information on 
suspected ADR, allowing the electronic exchange of reports of ADR cases, used by 
the various partners of the European regulatory network to monitor the safety of 
medicines [60].
A strong pharmacovigilance system can perform safety surveillance with pro-
cesses, tools, and experts to monitor ADRs from medication taken by older patients. 
During this post-authorization surveillance, safety risks may be detected, particu-
larly in patients with comorbidity and polypharmacy, suffering physiologic changes 
inherent to the aging process [61, 62]. Adequate pharmacovigilance systems 
considering HMPs is also necessary to increase the likelihood of ADR detection, and 
appropriately identify and manage older patients at risk [49, 63].
Risk management plans [RMP] must also be submitted to EMA when apply-
ing for a marketing authorization, including relevant information on medicine’s 
safety profile, how the risks will be prevented or minimized and how to promote 
knowledge regarding safety and efficacy of a determined drug.. The elaboration of 
this document allows the understanding of safety concerns in older adults, planning 
how to reduce the possibility of suffering ADR. The RMP must be modified when-
ever it is determined important safety risks, as well as the labeling [54, 64].
Nevertheless, signal detection using spontaneous reporting systems is one of the 
most important sources for safety monitoring in post authorization “real-life” set-
ting, especially in populations underrepresented in preapproval clinical trials such 
as older adults [61, 62]. Even tough underreporting, low sensitivity and selectivity 
are disadvantages to be considered regarding this reporting system, the fact that 
broadens all medicines on the market throughout all the life cycle, in all patients, 
not interfering with prescription habits, not only allows the identification of com-
mon ADR, as well as rare, unexpected ADRs in groups and scenarios not studied, as 
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the older patients. This makes spontaneous reporting a fundamental report system 
for the safety monitoring of approved medicines [60, 65]. Due to the widespread of 
under-reporting of ADRs to spontaneous reporting systems, including serious or 
severe ADRs, the use of new technology is a great opportunity to empower patients 
to report, such as the programmes WEB-RADR [66] in Europe and Medwatch [67] 
in the United States. Although these tools were developed to facilitate reporting by 
both healthcare professionals and patients, a better understanding of the relation 
that the older patients have with health technologies is need [68].
In the European Economic Area [EEA], the electronic transmission of infor-
mation from Pharmacovigilance became mandatory in November 2005, with 
EudraVigilance being the system for analyzing and managing information on 
suspected ADR, facilitating electronic exchange of individual case safety reports 
between EMA, national competent authorities, marketing authorization holders 
and sponsors of clinical trials in the EEA, as it allows early detection and evaluation 
of possible safety signals [60, 69].
EudraVigilance allows researchers and/or interested readers to perform same 
analysis in the ADR database EudraVigilance of the EMA, even though with 
different levels of access for different stakeholders. As some studies explore 
national databases, some studies have explored EudraVigilance database, accessing 
suspected medication and common ADR reported in older adults. Antineoplastic 
and immunomodulating agents, Nervous system, Cardiovascular system, Blood, 
and blood forming organs represent a significant part of suspected medication 
spontaneously reported in elderly. Rash, Confusional state, Dizziness, Pruritus, 
Pyrexia, Thrombocytopenia, Diarrhea, Vomiting, Dyspnea and Nausea are the most 
reported Preferred Terms in elderly spontaneous cases [62, 70, 71].
5. Conclusions
Older adults, having comorbidities, in polypharmacy regimens, associated with 
physiological age-related changes, are more susceptible to ADRs. With the demo-
graphic aging being a reality worldwide, the healthcare demand increases, as well as 
drug safety vigilance efforts.
Only recently older people start to have a significant presence in clinical trials. 
Pharmaceutical companies and the regulatory agencies joined efforts to provide 
evidence on the benefits and harms of medicines in older patients, giving more 
importance to efficacy and safety during drug development targeting diseases 
mostly related with aging or chronic diseases.
Pharmacovigilance regulatory agencies at a local and national level should pro-
mote monitoring and reporting programs of adverse effects observed, particularly 
in older populations, adding reliable safety data and identifying age related.
Drug safety studies in this age group need to be constantly improved to pres-
ent evidence-based data to enhance quality of prescriptions in a highly healthcare 
demanding age group.
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Appendices and Nomenclature
ADR Adverse drug reaction
CDSS Clinical decision support systems
CNS Central nervous system
EEA European Economic Area
EMA European Medicines Agency
FDA Food and Drug Administration
GFR Glomerular Filtration Rate
ICH International Council for Harmonization of Technical 
Requirements for Pharmaceuticals for Human Use
NSAID Non-steroid anti-inflammatory drug
RMP Risk Management Plan
SmPC Summary of Product Characteristics
WHO World Health Organization
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